Categories
Change Password!
Reset Password!
FDA approves enlicitide as the first oral PCSK9 inhibitor, delivering a groundbreaking once-daily pill option to slash "bad" cholesterol in adults battling HeFH.
On 17 July 2026, the U.S. Food and Drug Administration (FDA) authorized enlicitide, marking the introduction of the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) suppressor. The therapy is indicated, alongside diet and exercise, to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with hypercholesterolemia (HC), including individuals with heterozygous familial hypercholesterolemia (HeFH).
Until now, PCSK9 suppressors were available only as injectable medications. Enlicitide's once-daily oral tablet format marks a significant shift in accessibility, offering a needle-free alternative for adults who need further LDL-C reduction despite existing treatments. The approval underscores continued momentum in developing therapies for chronic cardiovascular disease care.
Why This Matters
This approval yields an additional option for those battling HC and reflects the FDA's broader commitment to supporting remarkable advances in patient access and mitigating chronic ailments.
HC occurs when there is excessive LDL-C in the blood. Over the years, elevated LDL-C may accumulate in arterial walls and promote plaque formation, which can reduce the space available for blood to flow. If a plaque ruptures, it may initiate clot formation and potentially lead to a heart attack or stroke. High cholesterol generally produces no noticeable symptoms, so it may go undetected until identified during a blood test. Factors such as overweight or obesity, dietary habits, sedentary behaviour, and inherited disorders can increase cholesterol levels.
Numerous drug classes are currently used to lower LDL-C, including ezetimibe, statins, and injectable PCSK9 suppressors. Enlicitide is the first oral therapy in the PCSK9 inhibitor class.
Clinical Trial Results at a Glance
The efficacy and safety of enlicitide were explored in two randomized controlled trials involving 3,207 adults with HC. Participants with and without HeFH were enrolled in the two trials, with all participants receiving their maximally tolerated statin regimen. The key outcome was the percentage alteration in LDL-C from baseline to week 24 vs. placebo.
Safety Profile
Regulatory Pathway
Enlicitide was granted Priority Review status for this indication. The application was also evaluated through the Commissioner’s National Priority Voucher (CNPV) pilot programme, which aims to expedite the assessment of therapies targeting key national public health needs.
U.S. FDA
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
Comments (0)